Check-Cap (NASDAQ:CHEK) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Saturday morning. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 3.8 %

Shares of NASDAQ:CHEK opened at $1.75 on Friday. Check-Cap has a twelve month low of $1.71 and a twelve month high of $4.63. The company has a market cap of $10.24 million, a PE ratio of -0.58 and a beta of 0.39. The company’s 50 day moving average is $1.93 and its 200 day moving average is $2.11.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.